🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06516653
Recruiting Not applicable

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

NCT06516653 · tracked via the Priya Life Science USA tracker
Sponsor
Laminate Medical Technologies
Phase
Not applicable
Started
2025-01-13
Last updated
2026-07-14

Condition(s) studied

End Stage Renal Disease

Investigational drug(s) / intervention(s)

VasQArteriovenous fistula creation for dialysis vascular access

VasQ: External support implant for the arteriovenous fistula

Arteriovenous fistula creation for dialysis vascular access: End to side fistula creation in the arm for dialysis vascular access

Study summary

VasQ is an external support implant for arteriovenous fistulas created for dialysis access.

This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized into two study arms:

* Treatment arm: End to side fistula supported with VasQ
* Control: Standard of care end to side fistula

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who are candidates for the creation of a new radiocephalic or brachiocephalic end-to-side surgical AV fistula for dialysis access (per VasQ IFU and investigator clinical judgment) and consent to take part in the study. 2. Male and non-pregnant female participants. 3. Age 18-80 years 4. Patients willing and able (physically and geographically) to attend follow up visits over a period of 12 months. Exclusion Criteria: 1. Index procedure being a revision surgery of an existing fistula. 2. Significantly stenotic target vein on the side of surgery (≥50%) as diagnosed on preoperative ultrasound. (Scan should include the full length of the expected fistula outflow, starting at the planned anastomosis site) 3. Unusual anatomy or vessel dimensions (observed on pre-operative ultrasound or intraoperatively) and which preclude adequate fit of the VasQ. 4. Known central venous stenosis or obstruction on the side of surgery. 5. Pre-existing stents or stent grafts in the access circuit. 6. Planned subsequent fistula superficialization procedure. 7. Known coagulation disorder. 8. Known allergy to nitinol. 9. Expected kidney transplant within 12 months of enrollment. 10. Inability to give consent and/or comply with the study follow up schedule. 11. Insufficient or borderline life expectancy to allow for completion of study procedures and follow-up (12 Months). 12. Participation in another interventional study that in the judgment of the investigator could confound study results.

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
Fresenius Vascular Care Long Beach Long Beach California Recruiting
Sarasota Memorial Hospital Sarasota Florida Recruiting
Grady Memorial Hospital Atlanta Georgia Recruiting
Brigham and Women's Hospital Boston Massachusetts Recruiting
Greenwood Leflore Hospital Greenwood Mississippi Recruiting
Azura Surgery Center Las Vegas Las Vegas Nevada Active Not Recruiting
Fresenius Vascular Care Columbia Columbia South Carolina Recruiting
Houston Methodist Hospital Houston Texas Recruiting
Fairlawn Surgery Center Roanoke Virginia Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06516653 on ClinicalTrials.gov ↗ ← All trials in the USA